Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids

Research unit

INNOSUISSE

Project number

101.972 IP-LS

Project title

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Alentis Therapeutics AG is implementing unique anti-claudin 1 monoclonal antibodies as a novel approach for the treatment of liver fibrosis. This project aims at leveraging 3D-in vitro models to identify translational makers of target engagement.